Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms- |
Target |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Castration-sensitive prostate cancer | Phase 1 | CA | 26 Mar 2024 | |
Castration-sensitive prostate cancer | Phase 1 | CA | 26 Mar 2024 | |
Metastatic castration-resistant prostate cancer | Phase 1 | CA | 26 Mar 2024 | |
Metastatic castration-resistant prostate cancer | Phase 1 | CA | 26 Mar 2024 | |
Oligometastatic Prostate Carcinoma | Phase 1 | CA | 26 Mar 2024 | |
Oligometastatic Prostate Carcinoma | Phase 1 | CA | 26 Mar 2024 | |
Prostatic Cancer | Preclinical | US | 24 May 2023 |